Insider sale: Bicara Therapeutics (BCAX) COO trades 3,828 shares

Rhea-AI Filing Summary

Bicara Therapeutics Inc. President and COO Ryan Cohlhepp, who is also a director, reported selling 3,828 shares of common stock on January 22, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025, which is designed to allow insiders to trade on a scheduled basis. The shares were sold at a weighted average price of $18.1024, with individual trade prices ranging from $18.00 to $18.19. Following this transaction, Cohlhepp directly beneficially owns 210,164 shares of Bicara common stock.

Insider Trade Summary

Net Seller: 3,828 shares ($69,296)

Net Sell 1 txn

Insider Cohlhepp Ryan

Role President and COO

Sold 3,828 shs ($69K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,828	$18.1024	$69K

Holdings After Transaction: Common Stock — 210,164 shares (Direct)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohlhepp Ryan

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		S(1)		3,828	D	$18.1024(2)	210,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bicara Therapeutics (BCAX) report?

Bicara Therapeutics reported that President and COO, and director, Ryan Cohlhepp sold 3,828 shares of common stock on January 22, 2026.

At what price did Ryan Cohlhepp sell Bicara Therapeutics (BCAX) shares?

The weighted average price for the 3,828 shares sold was $18.1024, with individual trades occurring between $18.00 and $18.19 per share.

How many Bicara Therapeutics (BCAX) shares does Ryan Cohlhepp own after the transaction?

After the reported sale, Ryan Cohlhepp beneficially owns 210,164 shares of Bicara Therapeutics common stock, held directly.

Was the Bicara Therapeutics (BCAX) insider sale part of a trading plan?

Yes. The sale on January 22, 2026 was executed under a Rule 10b5-1 trading plan that Ryan Cohlhepp adopted on February 12, 2025.

What role does Ryan Cohlhepp hold at Bicara Therapeutics (BCAX)?

Ryan Cohlhepp is a director of Bicara Therapeutics Inc. and serves as its President and Chief Operating Officer (COO).

How is the Bicara Therapeutics (BCAX) insider transaction categorized?

The transaction is reported as a sale of non-derivative common stock, coded as "S" for a sale in the Form 4.